Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Life-Threatening Delayed Myocardial Ischemia, Ventricular Arrhythmias, and SCD After PFA of AF: An Extended Case Series.

JACC. Clinical electrophysiology·2026
Same author

[Position paper of the German Society of Cardiology-quality criteria for performing catheter ablation of atrial fibrillation: executive summary].

Herzschrittmachertherapie & Elektrophysiologie·2026
Same author

Left atrial appendage closure in patients with non-valvular atrial fibrillation and end stage chronic KIDNEY disease: Rationale and design of the prospective randomized LAA-KIDNEY trial.

American heart journal·2026
Same author

Ultrasound-guided vs conventional venous puncture for atrial fibrillation ablation: the ULYSSES trial.

European heart journal·2026
Same author

Retraction notice to "Cognitive effects of cell-derived and synthetically-derived Aβ oligomers" [Neurobiol. Aging 32 (2009) 1784-1794].

Neurobiology of aging·2026
Same author

Severe cardiomyopathy due to permanent junctional reciprocating tachycardia: recovery after catheter ablation?-a case report.

European heart journal. Case reports·2026
Same journal

Incoming US science academy chief vows to 'double down' on research.

Nature·2026
Same journal

Author Correction: Synthesis of enantioenriched atropisomers by biocatalytic deracemization.

Nature·2026
Same journal

Electrodeposited self-assembled molecules for perovskite photovoltaics.

Nature·2026
Same journal

Neutrino's nursery found: the 'Shadow Blaster'.

Nature·2026
Same journal

Dementia risk in middle-aged people linked to a blood protein.

Nature·2026
Same journal

Daily briefing: What's really happening with trust in science.

Nature·2026
查看所有相关文章

相关实验视频

Updated: May 11, 2026

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms
06:40

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Published on: January 25, 2018

准基质的玛分泌酶调节器

Thomas L Kukar1, Thomas B Ladd, Maralyssa A Bann

  • 1Department of Neuroscience, Mayo Clinic, Mayo Clinic College of Medicine, 4500 San Pablo Road, Jacksonville, Florida 32224, USA. kukar.thomas@mayo.edu

Nature
|June 13, 2008
PubMed
概括
此摘要是机器生成的。

小分子玛分泌酶调节器 (GSMs) 准的是粉样蛋白前体蛋白 (APP) 和粉样β,而不是玛分泌酶复合体本身. 这种双重作用可能为阿尔茨海默病治疗提供一种协同方法.

更多相关视频

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase
11:57

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase

Published on: June 24, 2025

相关实验视频

Last Updated: May 11, 2026

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms
06:40

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Published on: January 25, 2018

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase
11:57

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase

Published on: June 24, 2025

科学领域:

  • 神经科学是一个神经科学.
  • 生物化学 生物化学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 阿尔茨海默病 (AD) 治疗的目标是使用玛分泌酶调节器 (GSMs) 降低粉样β 42 (Abeta42).
  • 在玛分泌酶通路内GSMs的精确分子标仍然不完全理解.
  • 识别GSM目标对于开发有效的AD疗法至关重要.

研究的目的:

  • 确定小分子玛分泌酶调节器 (GSMs) 的直接分子标.
  • 阐明GSM调节Abeta42产生和粉样β聚合的机制.
  • 探索基底向GSMs对阿尔茨海默病的治疗潜力.

主要方法:

  • 生物化可光激活GSM (光探测器) 的开发和应用.
  • 在人类神经质瘤H4细胞中进行亲和标记测试,以确定蛋白质点.
  • 用各种GSM进行竞争测试和基板特定标签实验.
  • 粉样蛋白前体蛋白 (APP) 结合部位的局部导向突变发生.

主要成果:

  • GSM光探测器标记了粉样蛋白前体蛋白 (APP),其碳氧终端片段和粉样β,但没有标记核心玛分泌酶组件.
  • GSM相互作用局限于粉样β的残留物28-36,这是聚合至关重要的区域.
  • GSMs改变了细胞衍生的粉样β oligomers 的产生,而 APP 突变影响了 GSM 灵敏度.
  • 对于APP而言,GSMs对基板进行标签的效率高于Notch.

结论:

  • GSM 通过直接准 APP 基质而不是玛分泌酶复合体而起作用.
  • 这种基质向机制将Abeta42产生的调制与抑制粉样β聚合联系在一起.
  • 这种双重行动为阿尔茨海默病提供了一个潜在的协同治疗策略,扩大了可药物点的概念.